Industry Watch
NHS inpatient survey shows modest improvements in patients’ overall experiences
24th September 2025
This survey, coordinated by Picker for the Care Quality Commission (CQC), examined patients' experiences of their hospital treatment that involved at least one overnight stay. The survey explored every aspect of their care from referral to after discharge from hospital.
The patients’ overall ratings of their care improved. Patients who rated their care as 9 out of 10 increased from 50.8% to 52.1%. However, 42% of people who had a planned hospital admission stated that they would have liked to have been admitted to hospital earlier. Also, 43% stated that their health became “a bit” or “much worse” whilst on the waiting list.
Skipping breakfast and its wide-ranging health consequences: A systematic review from multiple metabolic disruptions to socioeconomic factors
10th September 2025
The aim of the systematic review was to examine the impact of skipping breakfast across multiple health domains. This included diabetes, regulation of weight, composition of gut microbiome, neurodegenerative diseases, cardiovascular health, cancer, immunity, sleep cycles, psychiatric disorders, bone health, athletic performance, socioeconomic factors, and cognitive function.
The systematic review examined the literature from 2010 to 2025 and it evaluated 66 studies.
Semaglutide cuts risk of heart attack, stroke or death compared to tirzepatide in STEER study
10th September 2025
The aim of the STEER study was to examine the real-world occurrence of major adverse cardiovascular event (MACE) while being treated with semaglutide or tirzepatide for chronic weight management in standard clinical practice in the United States.
Semaglutide 2.4 mg (Wegovy®) showed a 57% greater reduction in the risk of stroke, heart attack, or death from any cause, in people with overweight or obesity and cardiovascular disease who remained on the treatment in comparison to tirzepatide. The result was found to be significant.
